Stephens Investment Management Group LLC Has $61.04 Million Stake in Medpace Holdings, Inc. $MEDP

Stephens Investment Management Group LLC lowered its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) by 11.3% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 118,726 shares of the company’s stock after selling 15,056 shares during the quarter. Stephens Investment Management Group LLC’s holdings in Medpace were worth $61,044,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Quent Capital LLC acquired a new stake in Medpace in the third quarter worth $25,000. Geneos Wealth Management Inc. grew its stake in shares of Medpace by 64.9% in the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after buying an additional 37 shares during the period. Employees Retirement System of Texas acquired a new position in Medpace during the 2nd quarter worth approximately $36,000. IFP Advisors Inc raised its stake in Medpace by 223.3% during the 2nd quarter. IFP Advisors Inc now owns 194 shares of the company’s stock worth $61,000 after buying an additional 134 shares during the period. Finally, Hantz Financial Services Inc. boosted its holdings in Medpace by 5,075.0% in the second quarter. Hantz Financial Services Inc. now owns 207 shares of the company’s stock worth $65,000 after acquiring an additional 203 shares in the last quarter. 77.98% of the stock is owned by institutional investors.

Insider Activity at Medpace

In other Medpace news, VP Susan E. Burwig sold 20,000 shares of the company’s stock in a transaction on Monday, November 24th. The stock was sold at an average price of $609.15, for a total value of $12,183,000.00. Following the completion of the transaction, the vice president owned 27,500 shares in the company, valued at $16,751,625. This represents a 42.11% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Kevin M. Brady sold 3,000 shares of the firm’s stock in a transaction on Friday, November 21st. The shares were sold at an average price of $590.35, for a total value of $1,771,050.00. Following the sale, the chief financial officer directly owned 6,000 shares of the company’s stock, valued at approximately $3,542,100. This represents a 33.33% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 387,925 shares of company stock valued at $233,386,647. 20.30% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on MEDP. Robert W. Baird set a $613.00 target price on Medpace in a research report on Friday, October 24th. Truist Financial set a $555.00 price objective on shares of Medpace in a report on Monday, October 27th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Medpace in a research note on Friday, October 31st. Zacks Research downgraded shares of Medpace from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 12th. Finally, BMO Capital Markets initiated coverage on shares of Medpace in a report on Thursday, November 13th. They issued a “market perform” rating and a $600.00 target price on the stock. Two investment analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and four have issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Reduce” and a consensus price target of $491.27.

Medpace Price Performance

NASDAQ MEDP opened at $610.90 on Friday. The company has a fifty day moving average price of $582.73 and a 200-day moving average price of $510.03. The firm has a market cap of $17.21 billion, a price-to-earnings ratio of 42.72, a PEG ratio of 2.08 and a beta of 1.43. Medpace Holdings, Inc. has a 1 year low of $250.05 and a 1 year high of $628.92.

Medpace (NASDAQ:MEDP) last released its quarterly earnings results on Wednesday, October 22nd. The company reported $3.86 earnings per share for the quarter, topping the consensus estimate of $3.50 by $0.36. Medpace had a net margin of 18.36% and a return on equity of 91.88%. The business had revenue of $659.90 million for the quarter, compared to analysts’ expectations of $640.49 million. During the same period in the previous year, the company earned $3.01 earnings per share. The firm’s revenue for the quarter was up 23.7% compared to the same quarter last year. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. On average, research analysts anticipate that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.